Fig. 3: Fer1 and DFO alleviate Crizotinib-triggered hepatotoxicity and ferroptosis.
A and B The survival rate of AML12 cells (A, n = 6) and HL-7702 cells (B, n = 3) treated with Crizotinib and/or DFO in different concentrations for 48 h. C57 male mice were treated with 120 mg/kg/day Crizotinib and/or 1 mg/kg/day Fer1 or 30 mg/kg/day DFO for 3 weeks. C and D The levels of serum ALT (C) and AST (D) were analyzed (n = 7–8). E Representative images of H&E staining in liver tissues (H&E staining, ×20). F The expression of SLC7A11 and GPX4 protein were measured by western blot (n = 6). G The GPX4 mRNA level was determined by RT-qPCR (n = 8). H–J GSH, the reduced GSH/HSSG (H, n = 8), total Iron concentration measured by reagent box and ICP-MS (I, n = 8), MDA and LPO (J, n = 8) were measured. K and L Representative pictures of 4-HNE expression in each group measured by immunohistochemical staining (K, ×20). And the staining outcomes were quantitatively assessed using the H-score system (L, n = 5). *P < 0.05, **P < 0.01 and ***P < 0.001 vs. control group. #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. Crizotinib group. Crizo Crizotinib.
